Key Takeaways
- • A private equity consortium led by European firms Cinven and Astorg has agreed to acquire LGC Group from KKR & Co, with the deal valued at approximately £3 billion ($3.88 billion) according to Financial Times reporting.
- • LGC, a British scientific measurement and testing company, generated significant value for KKR since its 2015 acquisition from Bridgepoint for £650 million, more than quadrupling in valuation through organic growth and strategic acquisitions.
- • The acquisition reflects strong institutional appetite for life sciences infrastructure and testing services, with Blackstone and Leonard Green previously competing for the asset, underscoring the sector's strategic importance and resilience.
- • Cinven and Astorg bring complementary expertise—Cinven's focus on pharmaceuticals and life sciences, and Astorg's broader exposure to healthcare, software, and technology-based industrial companies—positioning them to accelerate LGC's growth trajectory.
Summary
A consortium of European private equity firms has secured LGC Group, a leading British scientific measurement and testing company, from KKR & Co in a deal valued at approximately £3 billion ($3.88 billion). The buyer group, led by Paris-based Astorg and London-based Cinven, will acquire a business that has established itself as a critical infrastructure player across healthcare, regulatory compliance, and affiliated markets.
LGC's service portfolio spans specialized testing capabilities ranging from quality assurance for breweries to pathogenic detection in dairy products and forensic analysis of biological samples. The company maintains direct relationships with government bodies and regulatory agencies, creating structural stickiness within its revenue base. This business model attracted sustained institutional interest, with multiple tier-one alternative asset managers including Blackstone and Leonard Green pursuing the asset during the competitive process, according to Reuters.
KKR's ownership tenure since 2015 proved highly accretive to value. The New York-based firm acquired LGC from Bridgepoint for £650 million and executed a disciplined growth strategy anchored on strategic acquisitions and operational expansion, more than quadrupling the company's valuation over the four-year holding period. This outcome underscores the sector's fundamental strength and the attractive unit economics embedded within life sciences infrastructure and testing services.
The buyer consortium combines specialized sector expertise with broad platform capabilities. Cinven maintains a dedicated focus on the pharmaceuticals and life sciences vertical, while Astorg operates with diversified exposure across software, healthcare, business-to-business services, and technology-intensive industrial businesses. Astorg's managing partner Francois de Mitry emphasized five years of active monitoring and conviction in LGC's scientific capabilities, positioning the transition as a strategic continuation rather than a financial engineering exercise.
The transaction reflects ongoing institutional confidence in non-discretionary life sciences services and the durability of testing and compliance-driven revenue streams in regulated markets.
LGC's service portfolio spans specialized testing capabilities ranging from quality assurance for breweries to pathogenic detection in dairy products and forensic analysis of biological samples. The company maintains direct relationships with government bodies and regulatory agencies, creating structural stickiness within its revenue base. This business model attracted sustained institutional interest, with multiple tier-one alternative asset managers including Blackstone and Leonard Green pursuing the asset during the competitive process, according to Reuters.
KKR's ownership tenure since 2015 proved highly accretive to value. The New York-based firm acquired LGC from Bridgepoint for £650 million and executed a disciplined growth strategy anchored on strategic acquisitions and operational expansion, more than quadrupling the company's valuation over the four-year holding period. This outcome underscores the sector's fundamental strength and the attractive unit economics embedded within life sciences infrastructure and testing services.
The buyer consortium combines specialized sector expertise with broad platform capabilities. Cinven maintains a dedicated focus on the pharmaceuticals and life sciences vertical, while Astorg operates with diversified exposure across software, healthcare, business-to-business services, and technology-intensive industrial businesses. Astorg's managing partner Francois de Mitry emphasized five years of active monitoring and conviction in LGC's scientific capabilities, positioning the transition as a strategic continuation rather than a financial engineering exercise.
The transaction reflects ongoing institutional confidence in non-discretionary life sciences services and the durability of testing and compliance-driven revenue streams in regulated markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.